Pacific Biosciences (P09) Q3 2026 Earnings Report

The call was broadly positive, with improving SPRQ-Nx adoption, clinical growth above 20% year-over-year, stronger instrument placements, strategic clinical and AI partnerships, and continued progress toward operating expense reduction and a 2028 cash flow breakeven target. These positives were tempered by lower year-over-year consumables revenue, a decline in gross margin, constrained academic and government funding, a reduced cash balance, and ongoing regional and capital-spending challenges.

PacBio is narrowing full year revenue guidance to $155 million to $160 million, expects non-GAAP gross margin to be in the range of 35% to 37% for 2026, year-end cash of approximately $175 million to $185 million, and non-GAAP operating expenses in the range of $203 million to $207 million; it continues to expect full year consumables pull-through of $200,000 to $225,000 per Revio system, the vast majority of the installed base to opt in by year-end, cash burn to step down meaningfully in 2027, $15 million to $20 million in expected annual savings from reduced compensation-related expenses, an additional $15 million to $20 million in annual savings as development spending on the high throughput platform widens down, cash flow breakeven in 2028, a return back to that 225 to 250 pull-through range for consumables in 2027, and a commercial launch of the high throughput platform by the end of next year.